| Business Summary | | LifeCore
Biomedical,
Inc.
develops,
manufactures,
and
markets
biomaterials
and
surgical
devices
through
two
divisions:
the
Hyaluronan
Division
and
the
Oral
Restorative
Division.
The
Hyaluronan
Division
principally
is
involved
in
the
development
and
manufacture
of
products
utilizing
hyaluronan,
a
naturally
occurring
carbohydrate
that
moisturizes
or
lubricates
the
soft
tissues
of
the
body.
The
Hyaluronan
Division's
primary
development
project
involves
a
version
of
Lifecore's
patented
ferric
hyaluronan
technology,
GYNECARE
INTERGEL
Adhesion
Prevention
Solution,
which
is
a
second-generation
product
with
potential
application
in
reducing
the
incidence
of
post-surgical
adhesions.
The
Oral
Restorative
Division
markets
a
comprehensive
line
of
titanium-based
dental
implants
for
replacement
of
lost
or
extracted
teeth. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Lifecore
Biomedical,
Inc.
develops,
manufactures
and
markets
surgical
devices
through
two
divisions,
the
Hyaluronate
Division
and
the
Oral
Restorative
Division.
For
the
nine
months
ended
3/31/01,
net
sales
increased
6%
to
$25.2
million.
Net
loss
rose
from
$425
thousand
to
$1.8
million.
Revenues
reflect
higher
ophthalmic
and
orthopedic
bone-regeneration
hyaluronan
sales.
Higher
losses
reflect
unabsorbed
excess
capacity
costs
and
expenses
from
Lifecore
Germany. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
8,896;
after
tax
earnings
were
-1,913. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| John Bracke, Ph.D., 53 Pres,
CEO, Sec., Director | $319K | $42K | Dennis Allingham, 53 Exec.
VP, CFO | 203K | -- | Colleen Olson, 53 VP
of Corp. Admin. Operations | 146K | -- | Brian Kane, 53 VP
of New Bus. Devleopment and Marketing | 163K | -- | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|